

Reference

- Abass Ak, Lichtman AH and Pober JS (1999):** Recognition of antigens .In: Cellular and molecular immunology. 4th ed. Saunders company New York. Pp. 76 and 246.
- Adami F, Guarini A,Pini M.and Semenzato G.(1994):**Serum levels of tumor necrosis factor-alpha in patients with B-Cell chronic lymphocytic leukaemia (B-CLL) Eur J Cancer, 9:1259.
- Afifi A, Elsetouhy M, Elsharkawy M et al (2004):** Diabetic nephropathy as a cause of ESRD in Egypt: a six year study: Eastern Mediterranean Health Journal 10(4/5):620-626.
- Aguirre, V (2002):** Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 277:1531-1537.
- American Diabetes Association, (2001):** Screening for Diabetes. Diabetes Care; 24 (Suppl 1): S21-S24.
- American Diabetes Association (2002):** Nutrition Principle and Recommendation for the Treatment and Prevention of Diabetes and Related Complications. Diabetes Care; 25:S50-S60.
- American Diabetes Association (2004):** Nephropathy in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S79-S83.
- Andersen AR, Brochner-Mortensen J and Parving HH(2003):** Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296-3302.

- Appel GB, Radhakrishnan J, Avram MM, DeFronzo RA, Escobar-Jimenez F, Campos MM, Burgess E, Hille DA, Dickson TZ, Shahinfar S and Brenner BM(2003):** Analysis of metabolic parameters as predictors of risk in the RENAAL study. *Diabetes Care* 26:1402-1407,
- Arai, K, NishidaJ and Yokota, T. (1990):**Co-ordinate regulation of immune inflammatory responses by cytokines.*Rinsho-Byori, Eng, Abs*, 38:347.
- Araszkiewicz A, Dorota A. Zozulińska, Magdalena M. Trepńska and Bogna Wierusz-Wysocka (2006):** Inflammatory markers as risk factors for microangiopathy in type 1 diabetic patients on functional intensive insulin therapy from the onset of the disease *Diabetes Research and Clinical Practice* Volume 74, Issue 2, Supplement 1, 30 November, Pages S34-S40
- Aronson D, Rayfield EJ (2002):** How hyperglycemia promote atherosclerosis: molecular mechanisms. *Cardiovascular Diabetology*, I: 1-10.
- Aukrustp P ,Liabakk N-B, Muller F ,Lien E and Froland S (1994):** Serum level of Tumor Necrosis Factor -alpha (TNF – α) and soluble TNF Receptors in Human Immunodeficiency Virus Type I Infection-Correlations to Clinical Immunologic Parameters.*J .Inf.Dis.*,169:420-424.
- Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S and Thornalley PJ(2003):**Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. *Diabetes* 52:2110-2120.

- Bagby G C and Segal GM (1991):** Growth factors and the control of hemopoiesis. *Haematology Basic Principles and Practice* (Ed. Hoffman R, Benz EJ, Shattil SJ, et al.) Vol. 9; pp.97-112.
- Bahtiyar, G. (2004):** Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. *Curr. Diab. Rep.* 4:194-198.
- Bain BJ and Bates I (2001):** Basic hematology techniques. In: *Practical Hematology* ,(eds.) Lewis SM , Bain BJ and Bates I. 9th edition, Chapter 3 ,p.19-46, Churchill Livingstone .Philadelphia, London.
- Barnes D.J, Pinto J.R and Viberti G (1998):** The patient with diabetes mellitus. In: *Oxford textbook of clinical nephrology*, 2nd ed., Davidson, A.M.; Cameron, J.S.; Grunfeld, J.P.; Kerr, D.N.; Ritz, E. and Winearls, C.G. (eds.), Oxford, Oxford university press, (Pub.), Ch. (4.1), PP. 723.
- Basta G, Lazzerini G, Massora M (2002):** Advanced glycosylation end products activate endothelium through signal transduction receptors RAGE: A mechanism for amplification of inflammatory response. *Circulation* 105:816-822.
- Baud L and Ardaillou R (1995):** Tumor necrosis factor in renal injury, *Miner Electrolyte Metab* 21 , pp. 336–341.
- Baumgart HJ, and Standl E, (2001):** The atherosclerotic process and its exacerbation by diabetes. *Exp Clin Endocrinol Diabetes*; 109 (Suppl2): S457-S492.

Beckman JA, Creager MA, and Libby P, (2002): Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management .JAMA; 287(19): 2570-2581.

Bell JI, and Hockaday TDR, (2000): Diabetes Mellitus. In Concise Oxford Textbook of Medicine, Edited by John GG. Ledingham and David A Warrel , Oxford University Press,p.734-769.

Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, and Remuzzi G (1993): A specific endothelin subtype a receptor antagonist protects against injury in renal disease progression. Kidney Int: 44: 440-4.

Berg A.H, Combs T.P, and Scherer P.E (2002): ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13:84-89.

Bernhard Hellmich ,Matthias Schellner,Helmut Schatz, and Andreas Pfeiffer(2000):Activation of TGF beta1 in diabetic kidney disease.Metabolism Vol49,No 3(march);pp353-359

Beutler, B. and Cerami, A. (1988): Tumor necrosis, cachexia, shock and inflammation: a common mediator. Rev. Biochem. 57:50-55.

Beutler, B. and Van Huffel, C. (1994): Unraveling function in the TNF ligand and receptor families. Science, 264:667.

Beutler, B.A.; Greenwald, D. and Cerami, A. (1985(a): Identity of tumour cachectin.Nature, 316:552.

Beutler, B.A.; Mahoney, J.; Pakala, P. and Cerami, A. (1985(b):

- Bjorkbacka, H (2004):** Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. *Nat. Med.* **10**:416-421.
- Bloomgarden ZT., (1999):** Perspectives on the news: American Diabetes Association Annual Meeting. *Diabetes Care* 23 : 845 – 852, 2000
- Bluher, M. (2002) :** Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. *Dev. Cell.* 3:25-38.
- Boden G., (197):** Role of fatty acids in pathogenesis of insulin resistance in type 2 diabetes mellitus. *Diabetes* .46:3-10.
- Bosman DR, Winkler AS, Marsden JT, Macdougall IC and Watkins PJ (2001):** Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. *Diabetes Care* 24:495-499.
- Bradham CA, Plumpe J, Manns MP, Brenner DA and Trautwein C (1998):** Mechanisms of hepatic toxicity: tumor necrosis factor alpha-induced liver injury. *Am J Physiol*; 275: G387-G392.
- Brady H., Spertini O. Jimenez W. Brenner B. Marsden P and Tedder T (1992):** Neutrophils, monocytes, and lymphocytes bind to cytokine-activated kidney glomerular endothelial cells through L-selectin (lam-I) in vitro, *J Immunol* 149 pp. 2437–2444.
- Brito PL, Fioretto, and Drummond K (1998):** Proximal tubular basement membrane width in IDDM. *Kidney International*, 35:754-761.

- Brownlee, M. (2001):** Biochemistry and molecular cell biology of diabetic complications. *Nature*. 414:813-820.
- Bumgardner GL, Li J, Apte S, Heininger M and Frankel WL (1998):** Effect of tumor necrosis factor alpha and intracellular adhesion molecule-1 expression immunogenicity of murine liver cells in mice. *Hepatology*; 28:466-474.
- Burg MB, (1983):** Role of aldose reductions and sorbitol in maintaining the medullary intracellular milieu. *Kidney Int*; 33:635-641.
- Butkiewicz EK, Leibson C and O'Brien PC, (1995):** Insulin therapy for diabetic ketoacidosis. *Diabetes Care*; 18: 1187-1190.
- Byrne A and Reen DJ (2002):** Lipopolysaccharide induces rapid production of interleukin-10 by monocytes in the presence of apoptotic neutrophils. *J Immunol*; 168(4):1986-77.
- Caput D, Beutler BA and Hartog K (1986):** Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. *Proc. Natl. Acad. Sci., USA.*, 83:1670.
- Caramori ML, Fioretto P, and Mauer M (2000):** The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? *Diabetes* 49:1399-1408,
- Caramori M.L and Mauer M (2003):** Pathophysiology of renal complication. In: *Ellenberg & Rifkins's Diabetes Mellitus*, 6th ed.,

porte, D.; Sherwin R.S. and Baron, A. (eds.), McGraw-Hill, Medical publishing division, New York, (pub.), Ch. (42), P.P. 697.

Caramori ML, Fioretto P and Mauer M (2004): The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? *Diabetes* 49:1399-1408

Carlsen H, Moskaug JO, Fromm SH Blomhoff R (2002): In vivo imaging of NF-Kappa B activity. *J Immunol*; 168(3):1441-6.

Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, and Williams B(1975): An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci USA.*; 72:3666-3670.

Carswell P.R, Beutler B.A, Beisel TA: Tumour necrosis factor in cytotoxic effects and sarcoma in mice. *J. Immunol.* 88:240-246.

Castrillo, A. (2003): Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. *Mol. Cell.* 12:805-816.

Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A and Schleicher ED(2000): Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long-term diabetic rats. *J Am Soc Nephrol* 11:2324-2336.

Chan FKM, Spiegel RM and Lenardo M.J.(2000): A novel domain in TNF receptors mediates pre-ligand receptor assembly and signaling . *Scand, J. Immunol.*, 51(Suppl. I):29.

- Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin, B, and Hannedouche T (1999):** Abysmal prognosis of patients with type 2 diabetes entering dialysis. *Nephrol. Dial. Transplant.* 14:129
- Charriere, G. 2003.** Preadipocyte conversion to macrophage. Evidence of plasticity. *J. Biol. Chem.* 278:9850-9855.
- Chinnaiyan A, O'Rourke K, Tewari M and Dixit V(1995) :** FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis, *Cell* 81 pp. 505–512.
- Coggins CH, Breyer Lewis J, Caggiula AW, Castaldo LS, Klahr S and Wang SR (1998):** Differences between women and men with chronic renal disease. *Nephrol Dial Transplant*; 13:1430-1435.
- Coley WB (1894):** Treatment of inoperable malignant tumors with the toxin of erysipelas and the *Bacillus prodigiosus*. *Trans Am Surg Assoc.*; 12:183-212
- Collins R, Armitage J, Parish S, Sleight P and Peto R (2003):** MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. *Lancet* 361:2005-2016.
- Cox NJ, Friegge M, Micolae FL (1999):** Loci on chromosome 23 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican- American Nat .*Genet.* 21:213-215.
- Coyne D, Nickols M, Bertrand W and Morrison A (1992):** Regulation of mesangial cell cyclooxygenase synthesis by cytokines and glucocorticoids, *Am J Physiol* 263 pp. F97–F102.

- Craig KJ, Donovan K, Munnery M, Owens DR, Williams JD and Phillips AO(2003):**Identification and management of diabetic nephropathy in the diabetes clinic.Diabetes Care 26:1806-1811.
- Crayer PE (1993):** Hypoglycemia unawareness in IDDM .Diabetes Care 16(suppl 3):40-47.,1993.
- Crook M (2004):** Type 2 diabetes mellitus: a disease of the innate immune system? An update. Diabet Med; 21: 203–207
- Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R and Corti A (2002):** Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 1; 62(3):867-74.
- Dahlquist G, Stattin EL, and Rudberg S (2001):** Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy: a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 16:1382-1386.
- Dalla M, Saller A, Bortoloso E et al (2000):** Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 26 (4): 8-14.
- Dalla Vestra, Michele Mussap, Pietro Gallina, Marino Bruseghin, Anna Maria Cernigoi, Alois Saller, Mario Plebani and Paola Fioretto(2005):**Acute-Phase Markers of Inflammation and Glomerular Structure in Patients with Type 2 Diabetes .J Am Soc Nephrol 16: 78-82.

Danald S. and Fong, MD, MPH (2004): Diabetic Retinopathy
.Diabetes Care, 27:2540-2553.

Dawson M M.,(1991): Tumor necrosis factor. In lymphokines and interleukins. CRC Press. Inc. Boca Raton. Florida 1st ed Ch. 10, pp. 210-225.

DCCT The Diabetes Control and Complications Trial Research Group (1993) :The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986.

DCCT; Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2003): Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167.

De Cosmo S, Bacci S and De Cicco MLL (1994): Increased prevalence of cardiovascular disease, reduced insulin sensitivity in parents of IDDM patients with elevated albumin excretion rate. Diabetologia;37(supple I):A23.

De Perrot M, Sekine Y, Fischer S, Waddell Tk, McRae K, Liu M, Wigle DA and Keshavjee S (2002): Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med, 15;165(2):211-5.

Deancy MF, Zisman A, and Kettyle WN (2000): Diabetic ketoacidosis and hyperglycemia hyperosmolar nonketotic syndrome. *Endocrinal Metab Clin North Am* 29(4):683-705.

Decart T (1992):Microalbuminurea ;implication in micro vascular disease. *Diabetes Car*:15:1181-1191.

Defronzo R A.,(1995):Diabetic nephropathy : etiologic and therapeutic considerations. *Diabetes Rev.*, 3:510.

Defronzo RA.,(1997): Diabetic nephropathy. In: Ellenberg & Rifkin's *Diabetes mellitus*, 5th ed., Porte, D and Sherwin, R.S. , Medical publishing division, New York, (Pub.), Ch. (43), PP. 970-1007.

Defronzo R A.,(2003): Diabetic nephropathy. In: Ellenberg & Rifkin's *Diabetes mellitus*, 6th ed., Porte, D.; Sherwin, R.S. and Baron, A. (eds.), McGraw-Hill, Medical publishing division, New York, (Pub.), Ch. (43), PP. 723.

Deinum J, Chaturvedi N,(2002)The rennin-angiotensin system and vascular disease in diabetes. *Seminars in Vascular Medicine*; 2(2): 149-155.

Delany MF, Zisman A, and Kettyle WN (2000): Diabetic ketoacidosis and hyperglycemia hyperosmolar nonketotic syndrome .*Endocrinol Metab Clin North Am* .29(4):683-705

Dembic Z,Loetscher, H,Gubler V, Pan JCE and Lesslauer (1990): Two human TNF receptors have similar extracellular but distinct intracellular domain sequences .*Cytokine*, 22:2231.

Di Petrillo K, Coutermarsh B and Gesek FA (2003): Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. *Am J Physiol Renal Physiol* Jan;284(1): pF113-21
Diabetes; 47:859.

Dinarello CA, Cannon JC, and Wolff SM (1986): TNF (cachectin) is an endogenous pyrogen and induces the productions of IL-1. *J. Exp. Med.*, 163:1433.

Dipetrillo K and Gesek FA(2004): Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. *Am J Nephrol* 24 : 352 –359, .

Donald S, Fong, MD, Lloyd P, and Aiello, MD, PHD (20004): Diabetic Retinopathy. *Diabetes Care*, 27:2540-2553.

Drost EM and MacNee W (2002): Potential role of interleukin-8, platelet activating factor and tumor necrosis factor-alpha in the sequestration of neutrophils in the lung: effects on neutrophil deformability, adhesion receptor expression, and chemotaxis. *Eur J Immunol*; 32(2):393-403.

Eero Honkanen, Eeva von Willebrand, Anna-Maija Teppo, Tom Törnroth and Carola Grönhagen-Riska (1998) : Adhesion molecules and urinary tumor necrosis factor- α in idiopathic membranous glomerulonephritis *Cell Biology – Immunology – Pathology Kidney International* 53, 909–917;

- El Khodary M, Sidhom G, Elkhayat Z, Awadalla R and Ayoub D(1998):**IGF I and TNF in non insulin dependent diabetes patients with diabetic nephropathy. Egypt .J. Lab. Med. Vol:10 No 2 ;335-344.
- Epelman S, Neely GG, Ma LL, Gjomarkaj M, Pace E, Melis M, Woods DE and Mody CH (2002):** Distinct fates of monocytes and T cells directly activated by pseudomonas aeruginosa exoenzyme S. J Leukoc Biol; 71(3):458-68.
- Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel and Namiduru E (2001):** Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem. Nov;34(8):645-50.
- Erik MS, Stephan JL, Hans LH et al (2005):** Biochemical risk markers: a novel area for better prediction of renal risk. Nephrol Dial Transplant 20:497-508.
- Fan X, Subramaniam R, Weiss MF, Monnier VM (2003):**Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinas, nuclear factor kappa B and intracellular reactive oxygen species formation. Arch Biochem Biophys 2003 Jan 15; 409(2): p274-86
- Feinstein R and Graunfeld C(1992):** Role of cytokine in inducing hyperlipedemia .Diabetes .41 (sup 2):97-101.
- Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P,Williams R, Woody J and Maini RN(2004):**Anti-TNF alpha therapy of rheumatoid arthritis: what can we learn about chronic

disease. *Novartis Found Symp*; 256:53-69; discussion 69-73, 106-11, 266-9

Fernandez –Real JM, Gutierrez C Rcart W , Fernandez –Castaner and Soler JL(1997): the tumor necrosis factor $-\alpha$ gene N co 1 polymorphism influence es the relationship among iInsulin resistance, percent body fat ,and increased serum leptin levels. *Diabetes* 46:1468-1472.

Ferrero E (2004): Assessment of TNF alpha-induced endothelial damage through the loss of its barrier function. *Methods Mol Med*; 98:127-36.

Festa A, D’Agostino R, Howard G, Mykkanen L, Tracy RP and Haffner SM (2000): Chronic sub clinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation*; 102: 42–47

Fisher C. L and Nakamura R., (1976) : *Am . J. Clin Path.*, 66, 840.

Florez J.C, Hirschhorn J, and Altshuler D (2003) : The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. *Annu. Rev. Genomics Hum. Genet.* 4:257-291.

Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R(2004): The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. *Curr Pharm Des* 10 : 3385 –3394.

Fossati. P. (1980): *Clin Chem.* 26/2,226.

- Friedman AN, Hunsicker LG, Selhub J, Bostom AG(2004):** Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy Atherosclerosis .Jan; 172(1):121-5..
- Friedman FA(1999):** Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications .Diabetes Care;22(suppl 2):XXS65-71.
- Frohlich M, Imhof A and Berg G (2000):** Association between C-reactive protein and features of the metabolic syndrome: a population based study. Diabetes Care; 23: 1835–1839
- Fukuhara, A (2005):** Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307:426-430.
- Furuta, M. (2002):** Relationship of the tumor necrosis factor-alpha -308 A/G promoter polymorphism with insulin sensitivity and abdominal fat distribution in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 56:141-145.
- Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlova M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Grzeszczak W, and Crepaldi G (2002):** Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13:1615-1625.
- Gilbert RE and Cooper ME (1999):** The tubulo-interstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int;56:1627–37.

- Giovanni F, Strippoli , Salvatore Di Paolo, Raffaele Cincione, Anna M. Di Palma, Annalisa Teutonico, Giuseppe Grandaliano, Francesco P, Schena and Loreto Gesualdo (2003):** Clinical and therapeutic aspects of diabetic nephropathy .J NEPHROL ; 16: 487-499
- Giunti S, Barit D and Cooper ME (2006):** Diabetic nephropathy from mechanism to rational therapies. Minerva Med 97(3): 241-262.
- Goh, C.R. (1990):**Tumour necrosis factor in clinical practice. Am. Acad. Med. Singapora., 19:235.
- Goldsby RA, Kindt TJ and Osborne BA (2000):** Kuby Immunology, 4th ed. W.H. Freeman andCompany. New York. P 43, 311 and 384-90.
- Gomez-Chiari M, Hamilton TA, Egido J and Emancipator SN (1993):**Expression of IP-10, a lipopolysaccharide- and interferon- γ -inducible protein, in murine mesangial cells in culture, Am J Pathol 142 pp. 433–439.
- Gonen and Rubenstien(1978) :**Haemoglobin A1 and diabetes mellitus.Diabetologia,15:1.
- Gordon C and Wafisy D (1990):** Effect of TNF- alpha on immune function.J.Immunol. 144:1753-58.Diabetologia, 15:1.
- Grant WP, Sullivan R, and Sonenshine DE, (1997) :**Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon.J Foot Ankle Surg; 36:1.

- Gray PW, Aggarwal BB, and Benton CV (1984):** Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. *Nature*; 312:721-724.
- Graziella Bruno MD, Franco Merletti MD, Annibale Biggeri MD, Giuseppe Barger MD, Stefania Ferrero MD, Gianfranco Pagano MD and Paolo Cavallo Perin MD(2003):** Progression to Overt Nephropathy in Type 2 DiabetesThe Casale Monferrato Study *Diabetes Care* 26:2150-2155,
- Gross JL, Zelmanovitz T, Moulin CC, De Mello V, Perassolo M, Leitao C, Hoefel A, Paggi A and Azevedo MJ(2002):** Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. *Diabetes Care* 25:645-651.
- Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr and Stone NJ (2004):** Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 110:227-239.
- Guan Y, and Breyer MD (2001):** Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. *Kidney Int*; 60: 14-30.
- Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK and Donner DB(2004):** Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. *Am J Physiol Cell Physiol* Mar;286(3): pC547-55

- Hadjadj S, Belloum R, and Bouhanick B, (2001):** Prognostic value of the angiotensin-I converting enzyme D/I polymorphism for nephropathy in type 1 diabetes: a prospective study. J Am Soc Nephrol, 12, 541-9.
- Hadjadj S, Duly-Bouhanick B, Bekherras A, BrIdoux F, Gallois Y, Mauco G, Ebran J , and Marre M(2004):** Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes: Diabetes Metab. Feb;30(1):43-51 .
- Hanis CL, Boerwinkle E, Chakraborty R .(1996):** A genom wide search for human type 2 DM diabetes gene reveals a major susceptibility locus in chromosome 2 . Nat. Genet., 13:161-166.
- Hansen HP ,Tauber-Lassen E, Jensen BR and Parving HH(2002):**Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 62: 220-228.
- Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, Tsuamoto H, Tomoto T, Hayashi K, Fujita K, S and Niho Y (2001):** Outside-to-inside signal through the membrane tumor necrosis factor alpha induces E-selectin (CD62E) expression on activated human CD4+T cells. Immunol; 166:130-6.
- Harris MI, Cowie CC, Reiber G , Boyko E , and Stern M(1995):**Diabetes in America, 2nd ed ., Washington , DC :US. Government Printing Office.

- Harris MI., (2000):** Definition and Classification of DM. In: Diabetes mellitus .Edited by LeRoith D, Taylor SI, and Olfasky JM (2nd ed Lippincott William &Wilkins , Awolter Kluver Company, Philadelphia, New York,P:326-334.
- Hasegawa G, Nakano K and Kondo M (1995):** Role of TNF and IL-1 in the development of diabetic nephropathy, Nefrologia 15 pp. 1–4.
- Hasegawa G, Nakano K, Sawada M(1991):** Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int;40: 1007–1012.
- Hatada, E.N., Krappmann, D., and Scheidereit, C.(2000):** NF-kappaB and the innate immune response. Curr. Opin. Immunol. 12:52-58.
- Hattersley AT., (1998):** Heterogeneity in type 2 DM: Lesson from maturity onset diabetes of young. Diabetes Review International, 7:10-14.
- Heidland A,Sebekova K and Schinzeil R(2001):**AGEs and the progressive course of renal disease. Am J Kid Dis.Oct; 38(4supplI):S100-6.
- Henry R J (1974):** determination of creatinine by kinetic method. In: Clinical Chemistry, principle and techinques,2nd edition,Harper&Rowe,pp.525.
- Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, Takeuchi H, Yoshino G, and Adachi M: (2003):** Very low-density lipoprotein-apoprotein CI is increased in diabetic

nephropathy: Comparison with apoprotein CIII. *Kidney Int* 63:2171–2177.

Hirosumi, J (2002): A central role for JNK in obesity and insulin resistance. *Nature*. 420:333-336.

Holman RR (2000): Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ* 321:405-412,

Horikawa M, Iwasaki N, Hara M (1997): Mutation in hepatocyte nuclear factor 1 beta gene (TCF2) associated with MODY. *Nature. Genet.* 17: 384 -388.

Horton ES and Jeanrenard B., (1990) : Obesity and diabetes mellitus ,In Rifkin H ,Port D Jr (ed), Ellenberg and Rifkin Diabetes Mellitus: Theory and Practice .New York: Elsevier,457-463.

Hotamisligil S and Spiegelman B M (2000): TNF- alpha and insulin resistance of obesity . *Diabetes Mellitus: a fundamental and text*, edited by Derek Leroith , Simoeon I . Taylor, Jerrold M Olefsky, 2nd ed., 65:651- 659.

Hovind P, Rossing P, and Parving HH (2001): Progression of diabetic nephropathy.*Kidney. Int.*, 59:702.

Hovind P, Rossing P, Tarnow L and Parving HH (2003): Smoking and progression of diabetic nephropathy in type 1 diabetes. *Diabetes Care* 26:911-916.

Hsu H, Xiong J and Goedel DV (1995): The TNF receptor 1-associated protein TRADD signals cell death and NFkB activation, *Cell* 81 pp. 495–504.

Hugh R, Brady Yvonn M O' Meara, Barry M and Brenner (2005) Diabetes Mellitus. In *Harrison's Principles of Internal Medicine*. 16th ed. Chapter 264 page 1674-1701.

Hundal, R.S (2002). Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. *J. Clin. Invest.* 109:1321-1326. doi:10.1172/JCI200214955.

Hung J.H (2004): Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp38 mitogen-activated protein kinase. *J. Biol. Chem.* 279:46384-46392.

Iribarren C, Tolstykh I.V, and Eisner M.D (2004): Are patients with asthma at increased risk of coronary heart disease? *Int. J. Epidemiol.* 33:743-748.

Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M and Imai E (1999): Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extra cellular matrix accumulation in experimental glomerulonephritis. *Kidney Int*; 55: 465-75.

Ishii H, Jirousek MR, and Koya D.,(1996):Amelioration of vascular dysfunctions in diabetic rats by an oral PKC B inhibitor. *Science*; 272:728.

- Jo SK, Cha DR, Cho WY, Kim HK, Chang KH and Yun SY (2002):** Inflammatory cytokines and lypopolisaccharide induce Fas-mediated apoptosis in renal tubular cells, *Nephron* 91 pp. 406–415.
- Jorge L. Gross (2005):** Diabetic nephropathy: diagnosis, prevention, and treatment .*Diabetes Care* 28:176-188.
- Joseph, S.B. (2004):** LXR-dependent gene expression is important for macrophage survival and the innate immune response. *Cell*. **119**:299-309.
- Josephine M, Forbes, Mark E, and Merlin C Thomas (2003):** Role of advanced glycated end products in diabetic nephropathy *Am Soc Nephrol* 14:S254-S258.
- Kalantarinia K, Awas AS and Siragy HM (2003):** Urinary and renal interstitial concentrations of TNF- α increase prior to the rise in albuminuria in diabetic rats. *Kidney Int*; 64: 1208–1213
- Kasiske BL, (1998):** Hyperlipidemia in patients with chronic renal disease. *Am. J. Kidney. Dis.*, 32:142.
- Kathryn E. Wellen and Gokhan S. Hotamisligil (2005).** *J. Clin. Invest.* Inflammation, stress, and diabetes 115:1111–1119
- Keane W.F. (1999):** Lipids and progressive renal disease: the cardio-renal link. *Am. J. Kidney. Dis.*, 34: xliii.
- Kelber HC, Oppenheim J D, Aggarwal B A, and Stevenson H C, (1985):** Characterization of human TNF produced by peripheral

blood monocytes and its separation from lymphocyte. J. Immunol., 36:69.

Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson, Berka JL and Gilbert RE (2003): Protein kinase C [beta] inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512-518.

Kesavulu M, R. Giri R, Kameswara R, Apparao Ch (2000): Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications Diabetes Metab. Nov;26(5):387-92.

Khovidhunkit, W (2004): Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host [review]. J. Lipid Res. 45:1169-1196.

King H, Abert RA, and Herman WH (1998): Global burden of diabetes. Diabetes Care, 21:1414.

Klein BE, Klein SE, Moss A and Cruickshanks MJ (1998): The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes, Ophthalmology **105**, pp. 1801–1815.

Klein J and Horejsi V (1997): Cytokines and their receptors. In: Luther B and Travis (eds). Immunology. 2nd ed. Chapter 10 P 291, Blackwell Science. Ltd.. Oxford London.

Klein J and Horejsi V (2000): Immunology. 3rd ed. P 303-14 and 541-73. . Blackwell Science

- Knobler, H (2003) :**Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. *Am. J. Gastroenterol.* **98**:2751-2756.
- Korngold R, Marini JC, de Baca ME, Murphy GF and Giles-Komar J (2003):**Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. *Biol Blood Marrow Transplant* May;9(5): p292-303
- Koya D and king GL, (1998):** Protein Kinase C activation and the development of diabetic complications.
- Kull FC, and Cuatrecosa P.,(1985):**Preliminary characterization of the tumor cell cytotoxin in tumor necrosis serum. *J. Immunol.*, 126:1279.
- Laakso M and Lehto S,(1997):** Epidemiology of macrovascular disease in diabetes. *Diabetes Rev*; 5:294-315.
- Laffitte, B.A. (2003):** Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. *Proc. Natl. Acad. Sci. U. S. A.* **100**:5419-5424.
- Langham RG, Kelly DJ and Cox AJ (2002):** Proteinuria and the expression of the podocyte slit diaphragm protein nephrin in diabetic nephropathy: effects of angiotensin converting enzyme inhibitors. *Diabetologia*; 45:1572–6.

Laville M (2004): New strategies in anemia management ACORD (Anaemia Correction in Diabetes) trial. *Acta Diabetol* 41 (Suppl. 1):S18-S22.

Lechleitner M, Herold M, Dzien-Bischinger C, Hoppichler F, and Dzien A (2002): Tumor necrosis factor-alpha plasma levels in elderly patients with Type 2 diabetes mellitus-observations over 2 years. *Diabet Med.* Nov;19(11):949-53.

Lee, C.H (2003): Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. *Science.* 302:453-457.

Lee, C.H., Olson, P., and Evans, R.M. (2003): Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. *Endocrinology.* 144:2201-2207.

Li CZ, Xue YM, Gao F, and Wang M. (2004): Determination of serum highly sensitive C-reactive protein in patients with type 2 diabetes .*Di Yi Jun Yi Da Xue Xue Bao.* Jul;24(7):791-3.

Liao L, Lei MX, Chen HL, Wu J, and Guo LJ (2004):High-sensitive C-reactive protein and Type 2 diabetic nephropathy. *Zhong Nan Da Xue Xue Bao Yi Xue Ban.;* 29(6):627-30.

Lieberman A.P., Pitha P.M and Shin H.S. (1989): Production of TNF and other cytokines by strocytes stimulated with lipopolysaccaride or a neurotropic virus. *Pros Natle . Acod .Sci .USA .*86: 6348-52.

- Lin, Y (2005)** The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. *J. Biol. Chem.* 280:4617-4626
- Lippert J, Ritz E, and Schwarzbeck A(1995):** The rising of end stage renal failure from diabetic nephropathy type II : an epidemiologic analysis. *Nephrol Dial Transplant*, 10:462-7.
- Locksley RM, Killeen N and Lenardo MJ (2001):** The tumor necrosis factor alpha and tumor necrosis factor R super families: Integrating mammalian biology. *Cell*; 104:487-501
- Loetscher H, Pan JC, Lahm HW, and Lesslauer W (1990):** Glycation, Carbonyl stress, EAGLEs, and the vascular complications of diabetes. *Seminars in Vascular Medicine*; 2(2): 175-189.
- LoetscherH, Pan JC, Lahm HW, and Lesslauer W. (1990):**Molecular cloning and expression of the human 55 Kd tumor necrosis factor receptors. *Cell*, 61:351.
- Lord, G.M. et al. 1998. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature*. 394:897-901.
- Lorenzi M (1992):** Glucose toxicity in the vascular complication in diabetes: The cellular perspective. *Diabetes Metab Rev*;8:85.
- Lowell B.B and Shulman G.I(2005):** Mitochondrial dysfunction and type 2 diabetes. *Science*. 307:384-387.

- Lyons TJ., (2002):** Glycation, Carbonyl stress, EAGLES, and the vascular complications of diabetes. *Seminars in Vascular Medicine*; 2(2):175-189.
- MaCarthy E, Sharma R, and Sharma M (1998):** TNF- α increases albumin permeability of isolated rat glomeruli through the generation of superoxide. *J Am Soc Nephrol*; 9: 433–438
- Maeda, K. (2005):** Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. *Cell Metabolism*. 1:107-119.
- Mahmoud RA, El-Ezz SA, and Hegazy AS (2004):** Increased serum levels of interleukin-18 in patients with diabetic nephropathy. *Ital J Biochem*. Jul; 53(2):73-81
- Makino N, Toyoki M, Masahiro S, Shinji S, Reiko W and Nobuyuki A (2005):** High serum TNF- α level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells *Journal of Diabetes and its Complications* Volume 19, Issue 6 , November-December , Pages 347-355
- Makowski, L. (2001):** Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. *Nat. Med.* 7:699-705.
- Makowski, L and Hotamisligil G.S.(2004) :** Fatty acid binding proteins — the evolutionary crossroads of inflammatory and metabolic responses. *J. Nutr.* 134:2464S-2468S.

- Malmberg K , Yusuf, and Gerstien HC (2000):**Impact of diabetes on long term prognosis in patients with unstable angina and non Q wave myocardial infarction :result of the OASIS (Organization to Assess Strategies for Ischemic Syndromes)Registry. *Circulation*; 102:1014-1019.
- Marshall SM (2004): Recent advances in diabetic nephropathy.** *Postgraduate Medical Journal* 80: 624-633.
- McCarthy E, Sharma R, Sharma M, Li JZ, Ge XL and Dileepan K.N (1998):** TNF- α increases albumin permeability of isolated rat glomeruli through the generation of superoxide, *J Am Soc Nephrol* 9 pp. 433–438.
- Medina J, Baud L, García-Escribano C, Gila J, Rodriguez Puyol D and Rodriguez Puyol M (1993):** Tumor necrosis factor-induced contraction of cultured rat mesangial cells: interactions with angiotensin II, *J Lab Clin Med* 122 pp. 164–172.
- Merlin C,Thomas, Josephine M, Forbes, and Mark Cooper (2005):** Advanced glycated end Products and diabetic nephropathy .*American Journal of Therapeutic* 12,562-572.
- Meyer B –Davidson, MD (1998):** Diabetes mellitus diagnosis and treatment 4th ed. Chapter 8page 278-282.
- Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, and Egidio J (2004):** NF-kappa B activation and over expression of regulated genes in human diabetic nephropathy. *Nephrol Dial Transplant* 19 : 2505 –2512,
- Mittelman SD, Fu YY, Rebrin K, Steil G, Bergman RN, (1997):** Indirect effect of insulin to suppress endogenous glucose

production is dominant, even with hyperglucagonemia. *J Clin Invest*; 100:3121.

Mogensen CE (2000): Definition of diabetic renal disease in IDDM based on renal function tests. In Mogensen CE(ed). *The kidney and Hypertension in Diabetes Mellitus*, 5th ed. Boston, Kluwer, pp13-28 .

Mogensen CE (2003): Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. *J Intern Med* 254:45-66.

Moriwaki Y, Yamamoto T, Shibutani Y, Aoki E, Tsutsumi Z, Takahashi S, Okamura H, Koga M, Fukuchi M, and Hada T(2003): Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. *Metabolism*. May;52(5):605-8.

Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H(2007): Visfatin, an adipocytokine with proinflammatory and immunomodulating properties *J Immunol*. 2007 Feb 1;178(3):1748-58

Mulligan M, Johnson K, Todd R, Issekutz T, Migasaka M and Tamatani T (1993): Requirements for leukocyte adhesion molecules in nephrotoxic nephritis, *J Clin Invest* 91 pp. 577–587.

Navarro JF and Mora C(2005(a)): Role of inflammation in diabetic complications Nephrology Dialysis Transplantation 20(12):2601-2604

Navarro JF, Milena FJ, and Mora C I.(2005(c)) Tumor necrosis factor- α gene express on in diabetic nephropathy: relationship with urinary albumin excretion and effect of angioter sin-converting enzyme inhibition. Kidney Int; Dec ;(99):S98-102.

Navarro JF, Mora C and Rivero A(1999): Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis; 33: 458–463

Navarro JF, Mora C, Macía M, and García J(2003(b)): Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis; 42: 53–61.

Navarro JF, Mora C, Muros M, and García J (2005(b)):Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomised, controlled trial. J Am Soc Nephrol ; 16: 2119–2126

Navarro JF, Mora C, Muros M, and García J(2006); Urinary tumor necrosis factor- α excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephro Dial Transplant, Aug 25. .

Navarro JF, Mora C, Muros M, Macía M, and García J(2003(a)): Effects of pentoxifylline administration on urinary N-acetyl-beta-

glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. *Am J Kidney Dis*; 42: 264–270.

Nerlich A, and Schleicher E, 1991: Immunohistochemical localization of extra cellular matrix components in human diabetic glomerular lesions. *Am J Pathol*; 139:889-899.

Olsefsky JM and Kruszynska YT (2001): Type 2 diabetes mellitus: Etiology, pathogenesis, and the natural history .*Endocrinology* (4th edition). Edited by DeGoroot LJ and Jameson JL .WB Saunders Company, Philadelphia, and Vol. I p. 776-797.

Olsen S (2000): Light microscopy of diabetic glomerulopathy: the classic lesions. In Mogenson CE (ed): *The Kidney and Hypertension in Diabetes Mellitus*, 2nd ed .Boston, Kluwer Academic, pp 201-210.

Oppenheim, J.J.; Ruscetti, F.W. and Faltyynek, C. (1991): Cytokines. In *Basic and clinical immunology*, (7th ed.) Stites DP, and Terr AI, (eds.), Appleton and Lange, Norwalk Connecticut, (ch. 7, PP. 78-99).

Oppenheim JJ, Ruscetti FW, and Faltyynek C (1994): Cytokines. In *Basic and clinical immunology*, 8th ed. Edited by Stines, D .P., Terr , A.I., and Parslow , T. G. Appleton and Lange, P.105

Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M and Ritz E (1999): The ET (A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the “Fisher to Lewis” model. *J Am Soc Nephrol*; 10:387-91 .

- Ortiz A, Gonzalez-Cuadrado S and Bustos C (1995):** Tumor necrosis factor as a mediator of glomerular damage. *J Nephrol*; 8: 27–34
- Otto C ,Engleschak C ,Fraunberger P, and Laubach E,(2001):**Lack of association of urinary albumin excretion and IL-6 and CRP in patients with type 2 diabetes .*Acta Diabetes* ;38:153-155.
- Ozawa, K (2005):** The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. *Diabetes*. 54:657-663.
- Ozcan, U. (2004):** Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science*. 306:457-461.
- Palmabeilo VJ and Vilcek J (1989):** TNF is a bifunctional growth regulator in Blak/C3T3 cells.
- Pantsulaia T (2006):** Role of TGF-beta in pathogenesis of diabetic nephropathy .*Gorgea Med News* .Feb;(131):p13-8.
- Parring HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S and Arner P(2001):** The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 345:870-878.
- Pavenstadt H , Kriz W and Kretzler M (2003):** Cell biology of the podocyte. *Physiol Rev* 83:253–307.
- Paz, K (1997):** A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. *J. Biol. Chem*. 272:29911-29918.

Pedrini MT, Levey AS, Lau J, Chalmers TC and Wang PH(1996):

The effect of dietary protein restriction on the progression of diabetic and non diabetic renal diseases: a meta-analysis. *Ann Intern Med* 124:627-632.

Pennica D, Hayflick JS, Bringman TS, and Goedde DV, (1984):

Cloning and expression in escherichia coli of cDNA for murin tumour necrosis factor. *Proc. Natl. Acad. Sci., U.S.A.*, 82:6061.

Pennica D, Hayflick J S, Bringman T S, and Goedde DV ,(1985):

Cloning and expression in escherichia coli of cDNA for murin tumor necrosis factor .*Pro. Natl. Acad. Sci., U.S.A.*, 82:6061.

Peralta-Soler P, Mullin J, Knudsen K and Marano C (1996): Tissue

remodelling during tumor necrosis factor-induced apoptosis in LLC-PK1 renal epithelial cells, *Am J Physiol Renal Physiol* 270 pp. F869–F879.

Perry RC, Shankar RR, Fineberg M, (2001): HbA1c measurement

improves the detection of type 2 diabetes in high-risk individuals with non diagnostic levels of fasting plasma glucose.(The Early Diabetes Intervention Program (EDIP)).*Diabetes Care*; 24(3) 465-471.

Perseghin G, Petersen K, and Shulman G.I (2003): Cellular

mechanism of insulin resistance: potential links with inflammation. *Int. J. Obes. Relat. Metab. Disord.* 27(Suppl. 3):S6-S11.

Peter J, Watkins, Paul L, Drury, Simon L, and Howell (1996)

:*Diabetes and its management*. 5th ed. chapter 13 , page 143-150.

- Petrie A and Sabin C(2005):** Medical Statistics at a Glance. 2nd ed.,Blackwell Publishing,
- Philip Bernett and Glemn D Braunstien(2001):** Diabetes Mellitus. Diabetes mellitus In Cecil Essentials of Medicine, 5th ed. Chapter68, page 583 -598
- Pickup J and Crook M (1998):** Is type II diabetes mellitus a disease of the innate immune system? Diabetologia; 41: 1241–1248
- Pickup JC (2004):** Inflammation and activated innate immune system in the pathogenesis of type 2 diabetes. Diabetes Care; 27: 813–823
- Piguet P, Colla M A, Grau GE, Kapanci Y, and Vassalli P (1989):**Tumor necrosis factor (cachectin) plays a key role in bleomycin induced pneumopathy and fibrosis. J. Exp. ed., 170:655.
- Piguet, P.F. (1991):**Tumor necrosis factor and graft-versus host disease. Res., 40:111.
- Popper H., (1937):** Biochemz., 231 –359.
- Porta M, Sjoelie A K, Chaturvedi N, Stevens I, Rottiers R and Veglio M(2001):** Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB prospective complications study, Diabetologia **44** , pp. 2203–2209.
- Power AC (2001):** Diabetes Mellitus. In Harrison's Principles of Internal Medicine .15th ed. page 2109-2143.
- Power AC (2005):** Diabetes Mellitus. In Harrison's Principles of Internal Medicine .16th ed. Chapter 323 page 2152-2180.
- Price DL, Rhett PM, Thorpe SR, Baynes JW (2001):** Chelating activity of advanced glycation end-product inhibitors. J Biol

Chem;276:48867-72.

Raptis AE, Viberti G, (2001): Pathogenesis of diabetic nephropathy. Exp Clin Endocrinal Diabetes; 109 (suppl 2): S424-S437.

Ravid M, Brosh D, Ravid-Safran D, Levy Z and Rachmani R (1998): Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004.

Remuzzi, G.; Schieppati, A. and Ruggenti, P. (2002): Nephropathy in patients with type 2 diabetes.N. Engl. J. Med., 346:1145.

Ricci, R. . (2004): Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science. 306:1558-1561.

Richmond ,W.(1973):Clin Chem .19,1350

Ridger PM(2001):High-sensetivity C-reactive protien :Potential adjunct for global risk assesment in the primary prevention of cardiovascular disease.Circulation 103:1813-1818.

Riley MD and Dweyr T(1998): Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Am J Clin Nutr 67:50-57.

Ritz, E. and Stefanski, A. (1996): Diabetic nephropathy in type II diabetes. Am. J. Kidney Dis., 27:167.

- Robertson PR, Harmon J and Tanaka Y (2000):** Glucose toxicity of B-cell. Diabetes Mellitus, A fundamental and clinical text. Edited by LeRoith, D, Taylor SI and Olefsky JM .Lippincott Williams and Wilkins, Awolter Kluwer Company, Philadelphia, and Vol. I p. 125 -132.
- Robinson SC, Scott KA and Balkwill FR (2002):** Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous tumor necrosis factor alpha. Eur J Immunol; 32(2):404-12.
- Ros E, Nunez I, Perez-Heras A, Serra M, Gilabert R, Casals E and Deulofeu R (2004):** A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation 109: 1609-1614.
- Roschlau.p ,(1974):**J Clin Chem Clin Biochem. 12, 403
- Rose BD and Post TW (2001):** Clinical physiology of acid base and electrolyte disorders.5th ed.McGraw –Hill, New-York; PP794-806.
- Rosenberg, S.A. (1992):** The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:180
- Rossing P (2005):** Promotion, prediction, and prevention of progression in diabetic nephropathy. Diabetic Med 15:900–919.
- Roubenoff RA ,Cannon , JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, Dinarello CA and Roberse I (1994):** Rheumatoid cachexia :cytokine-driven hyper metabolism accompany reduced body cell mass in chronic inflammation .J Clin Invest;93(6):2379-86..

- Royal College of Physicians of Edinburgh Diabetes Register Group(2000):** Near-normal urinary albumin concentrations predict progression to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med. Nov;17(11):782-91
- Ruggenti P and Remuzzi G(1998):** Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 9:2157-2169.
- Ruilope . L.M. (1994):.** Randomly allocated study of the effects of standard therapy versus ACE inhibition on Micro-albuminuria in essential hypertension . j. Hypert . Suppl . : 12 : 559 –563
- Saghizadeh, M. (1996):** The expression of TNF alpha by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97:1111-1116.
- Saks, S. And Rosenbloom, M. (1992):.**Recombinant human TNF- α preclinical studies and results from early clinical trials.
- Saltiel, A.R and Pessin J.E(2002):** Insulin signaling pathways in time and space. Trends Cell Biol. 12:65-71.
- Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH(2003):**Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia. Oct;46(10):1402-7. Epub 2003 Aug 20.
- Sato A,;Hayashi K; Naruse M and Saruta T (2003):** Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64-68.

- Schaper NC, and Nabuurs-Franssen MH,(2002):** The diabetic foot: Pathogenesis and clinical evaluation. *Seminars in vascular Medicine*; 2(2):221-228.
- Schawalb D.M. ,Han H.M and Moriano M.(1993):**Identification of new receptor subtypes for TNF- α .*J Biol Chem.* ;268:9948-54.
- Schram MT, Chaturvedi N, SchalkwijkC, GiorginoF, EbelingP ,FullerJh and Stehouwer CDA (2005):** C.D.A., Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB prospective complications study, *Diabetologia* 48, pp. 370–378
- Schram MT,Chaturvedi N, SchalkwijkC, GiorginoF, EbelingP and FullerJh (2003):** CD vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes, the EURODIAB prospective complications study, *Diab. Care* 26, pp. 2165–2173.
- Seo, J.B..(2004):** Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. *Mol. Cell. Biol.* **24**:3430-3444.
- Sethi, J.K and Hotamisligil G.S. (1999):** The role of TNF alpha in adipocyte metabolism. *Semin. Cell Dev. Biol.* 10:19-29.
- Shalaby, M.R.; Loetscher, H. and Brockhaus, M. (1985):** Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumour necrosis factor.

- Shear MJ, Turner FC, and Perrault A (1943):** Chemical treatment of tumors: Isolation of the hemorrhage producing fraction from *Serratia marcescens* culture filtrate. *J Natl Cancer Inst.*; 4:81-97.
- Shikano M, Sobajima H, and Yoshikawa H (2000):** Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. *Nephron* ; 85: 81–5.
- Shimokawa T, Yamamoto K, Kojima T and Saito H(2000) :** Down-regulation of murine tissue factor pathway inhibitor mRNA by endotoxin and tumor necrosis factor alpha in vitro and in vivo, *Thromb Res* 100 pp. 211–221.
- Silkenase J R and Agrawal A (2005):** In Hand book of Nephrology and Hypertension ,5th ed. Chapter 7 ,page 43-49.
- Sinclair SH, DelVecchio C and Levin A (2003):** Treatment of anemia in the diabetic patient with retinopathy and kidney disease. *Am J Ophthalmol* 135:740-743.
- Slagle, D.C.; Cox, R.A. and Kuruganti, U. (1989):** Induction of tumor necrosis factor-alpha by spores of *Coccidioides immitis*. *Infect. Immunol.*, 57:1916.
- Spiegelman, B.M. (1998):** PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. *Diabetes*. 47:507-514.
- Springer TA (1990):** Adhesion receptors for the immune system.
- Staniforth V, Wang SY, Shyur LF and Yang NS (2004) :** Shikonins, phytochemicals from *Lithospermum erythrorhizon*, inhibit the

transcriptional activation of human tumor necrosis factor alpha promoter in vivo. *J Biol Chem* Feb 13;279(7): p5877-85

Steff M W; Bilous RW Sutherland DE and Mauer SM (1992): Cells and matrix components of glomerular mesangium in type I diabetes .*Diabetes* 41 :679-684.

Stephen Clement MD and Michael T McDermott M D (1998): Mitochondrial Diabetes. *Diabetes* Vol.47, p.1800-1802.

Stephen Clement MD and Michael T McDermott M D (2002): *Endocrine secrets* 3rd edition, chapter 3 ,page 32-39.

Steven C and Boyages MB (2000): The etiology of type 2 DM Diabetoraphia, 43:5-7.

Stoffers DA, Ferrer J, Clarke WL and Habner JF (1997): Early onset of type 2 DM (MODY-4) linked to IPFI .*Nature Genet*, 17:138.

Streja D, Cressey P, Rabkin SW (2003): Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. *J Diabetes Complications*.May-Jun;17(3):120-7 .

Sudhir V Shah,(2001): Glomerular Diseases in *Cecil Essentials of Medicine* 5th ed chapter pp253-265

Sugano M, Tsuchida K, Tomita H,and Makino (2002):Increased proliferation of endothelial cells with overexpression of soluble TNF-a receptor I gene, *Atherosclerosis* 162 , pp. 77–84.

Sugimoto H, Shikata K, Wada J, Horiuchi S, and Makino H (1999):

Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the over expression of tumor necrosis factor-alpha and inducible nitric oxide synthesis in diabetic rat glomeruli. . *Diabetologia* 1999 Jul; 42(7): p878-86

Suzuki D, 1998: Metalloproteinases in the pathogenesis of diabetic nephropathy. *Nephron*; 80: 125-133

Szotowski B, Antoniak S, Poller W, Schultheiss HP and Rauch U

(2005): Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines, *Circ Res* 96 pp. 1233–1239.

The ACE Inhibitors in Diabetic Nephropathy Trialist Group

(2001): Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin converting enzyme inhibitors? A metaanalysis of individual patient data. *Ann Intern Med* 134:370-379.

The Diabetes Control and Complications Trial Research Group

(1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329: 977-986.

The Expert Committee on the diagnosis and classification of

diabetes mellitus, (2001): Report of the Export Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*; 24 (Suppl 1): S5-S20.

- The Expert Committee on the diagnosis and classification of diabetes mellitus, (2003):** Report of the Export Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*; 26 (Suppl 1): S5-S20.
- Thiele DL and Lipskey RE (1982):** The accessory function of phagocytic cells in human T cell and B cell responses. *Immunol.*, 129:1033.
- Thomas MC, Forbes JM and Cooper ME (2005):** Advanced glycation end products and diabetic nephropathy. *Am J Ther* 12(6): 562-572.
- Thurman JM and Schrier RW (2003):** Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. *Am J Med* 114:588-598.
- Toeller M, Buyken A, Heitkamp G, Bramswig S, Mann J, Milne R and Gries FA, Keen H(1997):** Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. *Diabetologia* 40:1219-1226.
- Tong PC , Lee KF, So WY, Ng MH, Chan WB, Lo MK, Chan NN, Chan JC (2004):** White blood cell count is associated with macro- and microvascular complications in chinese patients with type 2 diabetes. *Diabetes Care*. Jan;27(1):216-22.
- Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee A.T, Kuo GC, Lowry SF and Cerami A (1987):** Anti cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia . *Nature*, 330:662-664.

- Trentin L, Zambello R, Agostini C, Pizzolo G, and Semenzato G (1993):** Expression and function role of tumor necrosis factor receptors on leukaemic cells from patients with type B chronic lymphoproliferative disorders.
- Trinder P (1969):** Enzymatic determination of glucose. *Ann.Clin.Biochem.* 5:24.
- UK prospective Diabetes Study (UKPDS) Group, (1998)** Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38).*BMJ*; 317: 703-713.
- Uysal, K.T (1997):** Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. *Nature.* 389:610-614.
- Van der kleij D, Van Remoortere A, Schuitemaker JH, Kapsenberg ML, Deelder AM, Tielens AG, Hokke CH and Yazdanbakhsh M (2002):** Triggering of innate immune responses by schistosome egg glycolipids and their carbohydrate epitope GalNAc beta 1-4 (Fuc alpha 1-2Fuc alpha 1-3) GlcNAc. *J Infect Dis* 15;185(4)531-9.
- Varfolomeev EE and Ashkenazi A(2004):**Tumor necrosis factor: an apoptosis JuNKie. *Cell* Feb 20;116(4): p491-7
- Vasan S, Foiles PG and Founds HW (2001).** Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links. *Expert Opin Investing Drugs*; 10: 1977-87.
- Vasylyeva TL, Chen X and Ferry JR (2005):** Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cells apoptosis, *Growth Horm IGF Res* 15 pp. 207–214.

- Viberti G and Wheeldon NM (2002):** Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. *Circulation* 106:672-678.
- Vinik AI, Park TS, Stansberry KB, Pittenger GL,(2000):** Diabetic neuropathies. *Diabetologia*; 43:957-973.
- Vora JP, Anderson S , and Brenner BM (1994) :** Pathogenesis of Diabetic glomerulopathy : The role of glomerular hemodynamic factors. In Mogensen CE, ed. *The kidney and Hypertension .In Diabetes Mellitus.2nd ed .Norwell, MA :Kluwer Academic Publishers;223-232.*
- Vora JP, Chattington PD, and Ibrahim H(2000):** Clinical Manifestations and Natural History of Diabetic Nephropathy. In Johnson RJ, Feehally J eds. *Comprehensive Clinical Nephrology*. London: Mosby Ed).
- Wallach D, Englemann H, Nophar Y,and Aderka D (1991):**Soluble and cell surface receptors for TNF.*Agents Actions Suppl.*, 35:51.
- Wallach,D.(2000):** TNF receptor family .In: Oppenheim,T.J. Feldman,M.,eds. *The cytokine reference*, Academic Press.
- Wallach,D.;VarfolomeevEE.;Malinin,n.L.;(1999):** TNF receptor and fas signaling mechanisms .*Annu. Rev. Immunol.*, 17:331-367.
- Wange UT, Michie HR and Spriggs DR (1985):** Detection of circulating TNF after endotoxin administration. *N. Engl. J. Med.*, 318:1481.

- Weisberg S.P. (2003)** :Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* 112:1796-1808. doi:10.1172/JCI200319246.
- Weyer C, Bogardus C, Tataranni PA and Pratley RE (2000):** Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. *Diabetes Care* 24:89-94.
- White and Bilous (2000):**Type 2 diabetic patients with nephropathy show structural functional relationship that are similar to type I disease .*Am J Soc Nephrol*,II:1667-1674.
- White KE, Bilous RW and Marshall SM(2002):** Podocyte number in normotensive type 1 diabetic patients with albuminuria. *Diabetes* ;51:3083–9
- Wilson PW and Culleton BF (1998):** Cardiovascular disease in the general population. *Epidemiology of cardiovascular disease in the United States.**Am. J. Kidney. Dis.*, 32:89.
- Winther MP, Kanters E, Kraal G and M.H. Hofker MH (2005):** Nuclear factor κ B signaling in atherogenesis, *Arterioscler. Thromb. Vasc. Biol.* 25, pp. 904–914.
- Witt I and Trendelenburg C,(1982)** : *J Clin Chem Clin Biochem*;20:235 – 242.
- Wolf, G and Ritz, E. (2003):** Diabetic nephropathy in type 2 diabetes: prevention and patient management .*J. Am. Soc. Nephrol.*, 14:1396.

- Xu, H.(2002):** Exclusive action of transmembrane TNF alpha in adipose tissue leads to reduced adipose mass and local but not systemic insulin resistance. *Endocrinology*. 143:1502-1511.
- Xu, H..(2003.):** Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Invest.* **112**:1821-1830. doi:10.1172/JCI200319451.
- Yagame M, kim Y, ZhuD ,Suzuki D, Nomoto Y, Sakai H and Mauer SM(1995):**Differential distribution of type IV collagen chain in patients with diabetic nephropathy in NIDDM. *Nephron*;70(1):p 42-8.
- Yu, C.(2002):** Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. *J. Biol. Chem.* 277:50230-50236.
- Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Brechot C and Zavala F (1999):** Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. *J Hepatol*; 30(2):185-91.